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Obesity is a chronic metabolic condition with important public health implications asso-
ciated with numerous co-morbidities including cardiovascular disease, insulin resistance,
and hypertension. The renin angiotensin system (RAS), best known for its involvement in
cardiovascular control and body ﬂuid homeostasis has, more recently, been implicated in
regulation of energy balance. Interference with the RAS (genetically or pharmacologically)
has been shown to inﬂuence body weight gain. In this study we investigated the effects of
systemic AT1 receptor blockade using losartan on ingestive behaviors and weight gain in
diet induced obese (DIO) rats. Prior to losartan administration (30 mg/kg/day) body weight
gain remained constant within the DIO animals (3.6 ± 0.3 g/day, n = 8), diet resistant
(DR) animals (2.1 ± 0.6 g/day, n = 8) and in the age-matched chow fed control (CHOW)
animals (2.8 ± 0.3 g/day, n = 8), Losartan administration abolished body weight gain in
animals fed a high fat diet (DIO: −0.4 ± 0.7 g/day, n = 8; and DR: −0.8 ± 0.3 g/day, n = 8)
while chow fed animals continued to gain weight (2.2 ± 0.3 g/day, n = 8) as they had
previously to oral administration of losartan. This decrease in daily body weight gain was
accompanied by a decrease in food intake in the HFD fed animals. Following the removal
of losartan, both the DIO and DR animals again showed daily increases in body weight
gain and food intake which were similar to control values. Our data demonstrate that oral
losartan administration attenuates body weight gain in animals fed a HFD whether the
animal is obese (DIO) or not DR while having no effect on body weight gain in age-matched
chow fed animals suggesting a protective effect of losartan against body weight gain while
on a HFD.
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INTRODUCTION
Obesity is a chronic metabolic condition with important pub-
lic health implications associated with numerous co-morbidities
including cardiovascular disease, insulin resistance, and hyper-
tension. Adipose tissue, once thought solely as a storage depot
for excess triglycerides, is now known to be an important
endocrine organ. Adipocytes produce and release a number of
adipokines, which have been shown to act centrally to inﬂuence
food intake and energy metabolism (see Woods et al., 1998; Galic
et al., 2010; Harwood, 2012; Williams and Elmquist, 2012 for
review).
The diet induced obesity (DIO) animal model is commonly
used to study obesity and its numerous co-morbidities. In con-
trast to genetic models of obesity, DIO develops as a consequence
of consuming a high fat diet (HFD) or high fat/high sugar diet
for a period of time and, thus, more closely mimics the etiology
of obesity in the majority of humans that display this pheno-
type. Interestingly, not all animals or people who prefer/consume
the HFD become obese, and these subjects are described as diet
resistant (DR; Levin et al., 1989; Smith and Ferguson, 2012). The
reason for this divergence is unknown (Levin et al., 1989). The
DIOphenotype is only partially explained by increased food intake
(Levin et al., 1989); obese animals on a HFD diet develop a resis-
tance to the actions of leptin (El-Haschimi et al., 2000; Lin et al.,
2000; Wang et al., 2001; Boyle et al., 2011), an adipokine shown to
be a key player in the control of food intake and energymetabolism
(see Friedman and Halaas, 1998; Jequier, 2002; Galic et al., 2010
for review).
While the renin angiotensin system (RAS) is best known for its
involvement in cardiovascular control and body ﬂuid homeosta-
sis, the RAS has more recently been implicated in the regulation
of energy balance. Not only does adipose tissue have a local RAS
(for review see Cassis et al., 2008; de Kloet et al., 2010; Frigolet
et al., 2013) but serum levels of all the components of the RAS
[renin, angiotensinogen (AGT), angiotensin (ANG) converting
enzyme] are elevated in obesity (Cooper et al., 1998; Yasue et al.,
2010). In addition, ANG receptors (Burson et al., 1994; Cran-
dall et al., 1994; Cassis et al., 1996) and all the components of
the RAS have been localized and been shown to be fully func-
tional in adipose tissue (Cassis et al., 1988; Engeli et al., 1999;
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Fowler et al., 2009), and expression of these components has been
shown to positively correlate with adiposity (Hainault et al., 2002;
Engeli et al., 2005; see Kalupahana and Moustaid-Moussa, 2012
for review). The RAS has also been implicated in energy expen-
diture, a key component in energy balance. Recent studies have
demonstrated that AGT deﬁcient (Agt−/−) mice or mice lack-
ing the AT1a receptor (Agtr1a−/−) have attenuated body weight
and adiposity when fed a HFD (Massiera et al., 2001; Kouyama
et al., 2005). These changes were accompanied by increased loco-
motor activity (Massiera et al., 2001) and rectal temperature and
O2 expenditure (Kouyama et al., 2005). The fact that both the
Agt−/− and Agtr1a−/− animals and their wild type counterparts
consumed the same amount of the HFD suggests that attenua-
tion of diet-induced weight gain and adiposity of the Agt−/− and
Agtr1a−/− animals may be due to the increased energy expen-
diture. Lastly, pharmacological manipulations of the RAS have
demonstrated an involvement for the RAS in body weight regu-
lation and composition in both obese (Stucchi et al., 2009; Miesel
et al., 2012; Premaratna et al., 2012) and non-obese animal mod-
els (Santos et al., 2008; Weisinger et al., 2008). As such, recent
attention has been directed toward the use of antagonists of the
RAS in the treatment of obesity (see Weisinger et al., 2009a for
review).
In light of these observations, the present studywas undertaken
to determine the inﬂuence of AT1 receptor blockade on nutri-
tional behavior and biometric development in obesity-resistant
and obesity-prone rats submitted to a HFD.
MATERIALS AND METHODS
All procedures were conducted in accordance with the Canadian
Council on Animal Care regulations and approved by Queen’s
University Animal Care Committee.
DIET INDUCED OBESITY
Upon arrival, male Sprague–Dawley rats (125–150 g) were housed
in pairs in a temperature controlled room on a 12 h light–
dark cycle and exposed to either a HFD (Research Diets, New
Brunswick, NJ #D12451, composition 45% kcal% fat, 35% kcal%
carbohydrate, and 20% kcal% protein) or standard chow diet
(LabDiet 5001, composition 13.5% kcal fat, 58% kcal carbo-
hydrate, and 28.5% kcal% protein) with water provided ad
libitum. Weight gain was measured on a weekly basis from time
of arrival until week 10 at which time animals exposed to the
HFD were divided into DIO or DR based on those who gained
the greatest and least weight, respectively. Animals that were
greater than 700 g were placed in the DIO group while ani-
mals that weighed less than 600 g were considered DR. Animals
that were of intermediate weights (600–700 g) were eliminated
from this study as they could not be reliably classiﬁed as DR or
DIO rats. The DIO and DR phenotypes were validated in accor-
dance with the DIO model of others (Levin and Dunn-Meynell,
2002; Hyland et al., 2007; Li et al., 2011) and in our own colony
(Smith and Ferguson, 2012).
Rats were continued on their respective diets and body weight,
food intake and water intake were measured daily between 8 am
and 10 am from week 17. After a control period of 14 days, the
ANG type 1 receptor (AT1R) antagonist, losartan (SigmaChemical
Company), was administered in the drinking water for 2 weeks at
30 mg/kg (Konno et al., 2012; Oliveira-Junior et al., 2014). Losar-
tan concentration was calculated daily for each animal based on
that day’s weight and the previous 24 h water consumption. Fol-
lowing the 2 week losartan treatment, animals were returned to
normal tap water for an additional 10 days.
DATA ANALYSIS
A one way analysis of variance (ANOVA) was used to determine
if body weights were different between animals in the DIO, DR,
and CHOW groups. Mean body weight gain, food intake/100 g
body weight, and water intake/100 g body weight were obtained
for each group (DIO, DR, and CHOW) for 7 days immediately
prior to losartan administration, days 1–7 and days 8–14 of losar-
tan treatment, and days 3–10 post losartan treatment. A repeated
measures ANOVA and post hoc Tukey multiple comparison tests
(p < 0.05 was considered as signiﬁcant) was used to determine
whether body weight gain, food intake, or water intake was altered
as a result of losartan treatment in each of the three groups (DIO,
DR, CHOW).
RESULTS
A total of 24 rats were used in this study of which 8 were
in the DIO group, 8 were in the DR group and 8 animals
were age-matched chow fed controls (CHOW). Rats classiﬁed
as DIO, based on weight gain after 10 weeks on the HFD, had
a mean body weight of 717.1 ± 12.4 g (n = 8). DR rats
weighed the same as age-matched chow fed controls (DR mean
body weight = 571.8 ± 16.5 g, n = 8; chow fed mean body
weight= 570.9± 18.4 g,n= 8;ANOVA p< 0.0001, chowvsDR,ns
Tukey post hoc analysis) andweighed signiﬁcantly less than the rats
classiﬁed asDIO (DIOvsDR,p< 0.001Tukey post hoc analysis; see
Figure 1).
At week 17, the beginning of daily body weight, food intake,
and water intake measurements, DIO rats weighed signiﬁcantly
more (DIO 892.6 ± 11.3 g, n = 8, p < 0.001 one way ANOVA)
than both the HFD fed DR rats (658.8 ± 16.4 g, n = 8, p < 0.05
Tukey post hoc analysis vs DIO) and chow fed control (CHOW)
FIGURE 1 | Diet Induced Obesity (DIO) Phenotype: mean weekly body
weight of rats classified as DIO (red circle) or diet resistant (DR, green
triangle) after 8 weeks of ad libitum feeding on a HFD and age-
matched chow fed controls (Chow, blue square) Bar graph on the right
shows the mean body weights of rats considered DIO or DR based on
those who gained the greatest and least weight, respectively, and
age-matched chow fed control animals at time of group assignment.
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animals (692.5 ± 25.2 g, n = 8, p < 0.001 Tukey post hoc analysis
vs DIO) while body weights of the DR and CHOW animals were
not signiﬁcantly different (p > 0.05 DR vs CHOW, Tukey post hoc
analysis).
Body weight increased steadily in all three groups (DIO, DR,
CHOW)during the 14 day control period (see Figure 2). However,
during losartan administration rats consuming theHFD (DIOand
DR) no longer demonstrated an increase in bodyweight while age-
matched chow fed control animals continued to gain weight as
they had previously to losartan administration (see Figure 2). As
illustrated in Figure 3,mean daily bodyweight gain remained con-
stantwithin all groups during the control periodwith age-matched
chow fed control animals (CHOW) demonstrating a mean body
weight gain of 2.8 ± 0.3 g/day (n = 8), DIO animals gaining
3.6 ± 0.3 g/day (n = 8) and DR animals gaining 2.1 ± 0.6 g/day
(n = 8). Losartan administration abolished body weight gain in
animals fed a HFD (DIO and DR, p < 0.001, repeated measures
ANOVA) while chow fed animals continued to gain weight as they
had prior to oral administration of losartan (p = 0.12, repeated
measures ANOVA; see Figures 2 and 3). This decrease in daily
body weight gain was accompanied by a decrease in food intake
(see Figure 4) in the HFD fed animals (DIO and DR, p < 0.001,
repeated measures ANOVA) while water consumption was not
altered (p > 0.05, repeated measures ANOVA; see Figure 4). Fol-
lowing the removal of losartan both the DIO and DR animals
again showed daily increases in body weight gain and food intake
which were similar to control values (see Figures 2–4). Losar-
tan administration was without effect on daily body weight gain,
food intake or water consumption in the chow fed animals (see
Figures 2–4).
DISCUSSION
Here, we assessed the effect AT1R blockade with losartan on body
weight and food intake in the rat DIO model of obesity. In line
with previous ﬁndings (Machado et al., 2012; Sagae et al., 2013;
Oliveira-Junior et al., 2014), we show that oral administration of
FIGURE 2 | Mean daily body weight in age-matched control rats fed standard rat chow (CHOW, upper panel), DIO rats (middle panel), and DR rats
(lower panel) before, during and after oral administration of losartan.Time of losartan administration indicated by the orange bar over the graphs.
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FIGURE 3 | Average daily weight gain in age-matched control rats
fed standard rat chow (CHOW; left) or in DIO rats (middle) or DR
rats (right), immediately prior to losartan treatment (Pre), days 1–7
(LOS 1–7) and days 8–14 (LOS 8–14) of losartan treatment and the
final 7 days (days 18–24) following losartan treatment (Post).
Losartan attenuated body weight gain in DIO and DR animals as
compared to control (*p < 0.05, **p < 0.01, ***p < 0.001; Tukey
post hoc analysis).
FIGURE 4 | Mean daily food (left panel) and water (right panel)
intake for 7 days immediately prior to losartan treatment (Pre),
days 1–7 (LOS 1–7) and days 8–14 (LOS 8–14) of losartan
treatment and the final 7 days (days 18–24) following losartan
treatment (Post). Food intake was decreased in DIO and DR animals
during losartan treatment compared to control values (*p < 0.05,
**p < 0.01, ***p < 0.001; Tukey post hoc analysis) while losartan
treatment had no effect on food intake in age-matched chow fed
controlanimals compared to control food intake. Water intake was
unaffected in all groups.
losartan abolishes weight gain in DIO rats fed a HFD without
inﬂuencing body weight in age-matched chow fed, animals. Our
study, however, extends these ﬁndings to show that AT1R receptor
blockade also prevents weight gain in animals fed a HFD but who
were not obese (DR animals).
A role for AT1R in the development of DIO is supported by
studies in AT1R knockout mice (Agtr1a−/−) that show an attenu-
ation of diet induced body weight gain as compared to their wild
type counterparts (Kouyama et al., 2005). Blockade of AT1R by a
variety of pharmacological agents have also been shown to prevent
HFD induced body weight gain (Sharieh Hosseini et al., 2014) or
to impair body weight gain in DIO animals (Machado et al., 2012;
Miesel et al., 2012; Sagae et al., 2013; Oliveira-Junior et al., 2014).
An interesting ﬁnding of the present study is that AT1R blockade
had a similar effect on weight gain in the DR animals but not in
age-matched chow fed controls suggesting a role for the RAS on
body weight gain only in animals receiving a HFD regardless of
body weight and adiposity. This ﬁnding may in part be explained
by the losartan-induced decrease in food intake, however, further
studies to elucidate the mechanism(s) by which blockade of the
RAS with losartan is able to prevent body weight gain in animals
fed a HFD are warranted, though decreased leptin and increased
adiponectin concentrations have already been proposed (Zorad
et al., 2006; Weisinger et al., 2009b; Premaratna et al., 2012). In
the present study, losartan administration did not change body
weight gain in age-matched chow fed (CHOW) animals a ﬁnding
that is at odds with previous work where administration of AT1R
antagonists attenuated body weight gain in rats fed a normal diet
(Zorad et al., 2006). These apparently contradictory ﬁndings may
be due to the differences in duration of AT1R antagonist adminis-
tration (14 days in the current study vs 18 week administration in
the Zorad et al. (2006), study differences in strain of rat, or in the
AT1R antagonist used. The fact that water consumption was not
altered by losartan suggests that the losartan-induced drop in food
intake observed in our study is not due to any secondary effect such
as the satiety that results from increased water consumption.
The data we present here raises important questions that
will require further studies to elucidate the mechanism(s) by
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which losartan exerts its protective effects on body weight gain
in the response to a HFD. Future studies investigating alterations
in energy expenditure as well as body composition may pro-
vide insights regarding speciﬁc mechanisms underlying losartan’s
ability to inhibit weight gain. Analysis of circulating concentra-
tions of the RAS and subsequent vascular and adipose reactiv-
ity to angiotensin II may also provide important information.
Finally, measurement of circulating metabolic hormones (leptin,
adiponectin,. . ..) and hypothalamic neurotransmitters (αMSH,
NPY, . . ..) prior to, during, and post losartan treatment may
uncover mechanisms through which the AT1 receptor modulates
these systems. Collectively, such future studies will likely eluci-
date the complexity through which the AT1 receptor activation
participates in the pathophysiology of adiposity.
CONCLUSION
Our data clearly demonstrates that oral losartan administration
attenuates body weight gain in animals fed a HFD whether the
animal is obese (DIO) or not (DR) while having no effect on body
weight gain in age-matched chow fed animals.We hypothesize that
angiotensin system blockade has a protective effect on bodyweight
gain while on a HFD. Our data suggests that the value of losartan
may extend beyond that of the treatment of hypertension andmay
be indicated as a suitable treatment for metabolic syndrome, the
conﬂuence of cardiovascular risk factors including hypertension,
abdominal obesity, dislipidemia, and type 2 diabetes.
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